Local treatments: surgery and radiotherapy
Treatment splits into two ideas: local treatments that attack the tumour where it sits, and systemic treatments that travel through the whole body to reach cells everywhere. For early-stage NSCLC that has not spread, surgery offers the best chance of cure. The surgeon removes the cancer with a margin of healthy tissue — sometimes a whole lobe of the lung — along with nearby lymph nodes to check for spread. This only works when the stage is low enough and the person's lungs and overall fitness can tolerate the operation.
Radiotherapy uses precisely aimed radiation to kill cancer cells, and it plays several roles. For an early tumour in someone who cannot have surgery, focused high-dose radiation can be an alternative with the aim of cure. For more advanced disease it is combined with chemotherapy. And it can ease symptoms — relieving pain from a bone metastasis or stopping bleeding — even when cure is not possible.
Systemic treatments: three families of drugs
When cancer has spread — or to mop up cells that may have escaped after surgery — the answer is systemic drug therapy, which now comes in three broad families. Chemotherapy uses powerful drugs that kill fast-dividing cells throughout the body; it is effective but blunt, harming some healthy fast-growing cells too, which causes its familiar side effects. For decades it was almost the only option for spread disease, and it still anchors treatment of small-cell lung cancer.
Targeted therapy is the precision approach. If a tumour carries a driver fault such as an EGFR mutation, a matching pill can switch off the exact signal the cancer depends on. These drugs are often taken at home, can work dramatically, and spare many of the cells chemotherapy would harm — but they only help when the matching marker is present, which is why the molecular testing from the previous guide matters so much.
Immunotherapy works differently again: instead of attacking the cancer directly, it releases the brakes on the body's own immune cells so they can recognise and destroy the tumour. The most-used type blocks the PD-1/PD-L1 “off switch” that cancers exploit to hide. For some people with advanced lung cancer it has produced durable responses unthinkable a decade ago. It can over-activate the immune system against healthy organs, so it is given with careful monitoring.
- Confirm the subtype: NSCLC versus SCLC sets the whole strategy.
- Establish the stage with TNM and a metastasis search to know if disease is local or spread.
- Test molecular markers and PD-L1 to see if targeted therapy or immunotherapy fits.
- Weigh the person's fitness, wishes, and goals, then combine the right local and systemic treatments.
Living well, whatever the stage
Not every lung cancer can be cured, but every person with lung cancer can be helped. Palliative care focuses on comfort, breathing, pain, and quality of life, and it is not a last resort — started early, alongside cancer treatment, it helps people feel better and sometimes even live longer. Stopping smoking, staying active, treating breathlessness, and supporting mood and family are part of good care at every stage.